gilead sciences europe ltd.
gilead sciences europe ltd. Company Information
Company Number
05510315
Website
www.gilead.comRegistered Address
2 roundwood avenue, stockley park, uxbridge, middlesex, UB11 1AF
Industry
Other business support service activities n.e.c.
Telephone
02085872200
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
gilead sciences ireland unlimited company 100%
gilead sciences europe ltd. Estimated Valuation
Pomanda estimates the enterprise value of GILEAD SCIENCES EUROPE LTD. at £439.5m based on a Turnover of £343.7m and 1.28x industry multiple (adjusted for size and gross margin).
gilead sciences europe ltd. Estimated Valuation
Pomanda estimates the enterprise value of GILEAD SCIENCES EUROPE LTD. at £898.9m based on an EBITDA of £90m and a 9.99x industry multiple (adjusted for size and gross margin).
gilead sciences europe ltd. Estimated Valuation
Pomanda estimates the enterprise value of GILEAD SCIENCES EUROPE LTD. at £399.7m based on Net Assets of £157.5m and 2.54x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Gilead Sciences Europe Ltd. Overview
Gilead Sciences Europe Ltd. is a live company located in uxbridge, UB11 1AF with a Companies House number of 05510315. It operates in the other business support service activities n.e.c. sector, SIC Code 82990. Founded in July 2005, it's largest shareholder is gilead sciences ireland unlimited company with a 100% stake. Gilead Sciences Europe Ltd. is a established, mega sized company, Pomanda has estimated its turnover at £343.7m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Gilead Sciences Europe Ltd. Health Check
Pomanda's financial health check has awarded Gilead Sciences Europe Ltd. a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 2 areas for improvement. Company Health Check FAQs
7 Strong
1 Regular
2 Weak
Size
annual sales of £343.7m, make it larger than the average company (£3.8m)
£343.7m - Gilead Sciences Europe Ltd.
£3.8m - Industry AVG
Growth
3 year (CAGR) sales growth of 9%, show it is growing at a faster rate (3%)
9% - Gilead Sciences Europe Ltd.
3% - Industry AVG
Production
with a gross margin of 38.8%, this company has a comparable cost of product (38.8%)
38.8% - Gilead Sciences Europe Ltd.
38.8% - Industry AVG
Profitability
an operating margin of 25.7% make it more profitable than the average company (6.3%)
25.7% - Gilead Sciences Europe Ltd.
6.3% - Industry AVG
Employees
with 512 employees, this is above the industry average (24)
512 - Gilead Sciences Europe Ltd.
24 - Industry AVG
Pay Structure
on an average salary of £229.2k, the company has a higher pay structure (£50.5k)
£229.2k - Gilead Sciences Europe Ltd.
£50.5k - Industry AVG
Efficiency
resulting in sales per employee of £671.4k, this is more efficient (£157.9k)
£671.4k - Gilead Sciences Europe Ltd.
£157.9k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Gilead Sciences Europe Ltd.
- - Industry AVG
Creditor Days
its suppliers are paid after 22 days, this is quicker than average (33 days)
22 days - Gilead Sciences Europe Ltd.
33 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Gilead Sciences Europe Ltd.
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 70 weeks, this is more cash available to meet short term requirements (24 weeks)
70 weeks - Gilead Sciences Europe Ltd.
24 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 39.6%, this is a lower level of debt than the average (63.7%)
39.6% - Gilead Sciences Europe Ltd.
63.7% - Industry AVG
GILEAD SCIENCES EUROPE LTD. financials
Gilead Sciences Europe Ltd.'s latest turnover from December 2022 is £343.7 million and the company has net assets of £157.5 million. According to their latest financial statements, Gilead Sciences Europe Ltd. has 512 employees and maintains cash reserves of £129.9 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 343,734,000 | 295,145,000 | 290,786,000 | 265,796,000 | 246,278,000 | 223,230,000 | 158,330,000 | 140,913,000 | 102,119,000 | 78,976,000 | 55,130,000 | 43,817,000 | 39,505,000 | 36,996,000 |
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | ||||||||||||||
| Operating Profit | 88,263,000 | 74,389,000 | 68,066,000 | 57,306,000 | 54,664,000 | 63,874,000 | 7,145,000 | 7,434,000 | 793,000 | -110,000 | -3,068,000 | -2,286,000 | -25,000 | -967,000 |
| Interest Payable | 162,000 | 237,000 | 397,000 | 500,000 | 66,000 | 2,173,000 | 13,000 | 1,000 | 23,000 | 58,000 | 42,000 | 57,000 | 0 | 0 |
| Interest Receivable | 2,063,000 | 46,000 | 361,000 | 1,046,000 | 335,000 | 108,000 | 82,000 | 71,000 | 55,000 | 33,000 | 11,000 | 6,000 | 1,000 | 8,000 |
| Pre-Tax Profit | 90,164,000 | 74,198,000 | 68,030,000 | 57,852,000 | 54,933,000 | 61,809,000 | 7,214,000 | 7,504,000 | 825,000 | -135,000 | -3,099,000 | -2,337,000 | -24,000 | -959,000 |
| Tax | -16,403,000 | -13,699,000 | -12,922,000 | -12,035,000 | -8,936,000 | -39,110,000 | -3,605,000 | -3,405,000 | -1,528,000 | -3,917,000 | 2,904,000 | -512,000 | -700,000 | -1,487,000 |
| Profit After Tax | 73,761,000 | 60,499,000 | 55,108,000 | 45,817,000 | 45,997,000 | 22,699,000 | 3,609,000 | 4,099,000 | -703,000 | -4,052,000 | -195,000 | -2,849,000 | -724,000 | -2,446,000 |
| Dividends Paid | 158,331,000 | 0 | 100,000,000 | 28,640,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -84,570,000 | 60,499,000 | -44,892,000 | 17,177,000 | 45,997,000 | 22,699,000 | 3,609,000 | 4,099,000 | -703,000 | -4,052,000 | -195,000 | -2,849,000 | -724,000 | -2,446,000 |
| Employee Costs | 117,325,000 | 106,438,000 | 91,781,000 | 69,810,000 | 72,760,000 | 55,744,000 | 52,626,000 | 46,900,000 | 36,417,000 | 33,357,000 | 24,658,000 | 19,128,000 | 14,046,000 | 14,728,000 |
| Number Of Employees | 512 | 435 | 390 | 345 | 306 | 287 | 270 | 230 | 198 | 152 | 129 | 115 | 102 | 98 |
| EBITDA* | 89,963,000 | 77,865,000 | 71,364,000 | 61,010,000 | 57,492,000 | 66,475,000 | 9,661,000 | 8,776,000 | 2,569,000 | 928,000 | -1,718,000 | -1,013,000 | 1,218,000 | 192,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 6,932,000 | 9,239,000 | 12,298,000 | 14,685,000 | 8,811,000 | 11,457,000 | 13,008,000 | 14,725,000 | 2,200,000 | 2,760,000 | 3,138,000 | 4,406,000 | 5,333,000 | 6,095,000 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 9,453,000 | 5,189,000 | 3,327,000 | 2,934,000 | 2,769,000 | 3,019,000 | 84,000 | 280,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 16,385,000 | 14,428,000 | 15,625,000 | 17,619,000 | 11,580,000 | 14,476,000 | 13,092,000 | 15,005,000 | 2,200,000 | 2,760,000 | 3,138,000 | 4,406,000 | 5,333,000 | 6,095,000 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 92,000 | 0 |
| Group Debtors | 99,708,000 | 97,152,000 | 77,581,000 | 13,023,000 | 70,039,000 | 79,555,000 | 28,141,000 | 31,894,000 | 17,698,000 | 18,195,000 | 9,255,000 | 3,450,000 | 3,256,000 | 2,224,000 |
| Misc Debtors | 14,520,000 | 12,547,000 | 10,701,000 | 13,734,000 | 9,459,000 | 9,021,000 | 10,260,000 | 8,544,000 | 8,656,000 | 5,724,000 | 5,362,000 | 2,964,000 | 2,470,000 | 2,417,000 |
| Cash | 129,890,000 | 203,329,000 | 129,231,000 | 213,039,000 | 123,087,000 | 66,223,000 | 45,292,000 | 20,966,000 | 21,900,000 | 10,573,000 | 10,313,000 | 7,333,000 | 1,322,000 | 6,639,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 244,118,000 | 313,028,000 | 217,513,000 | 239,796,000 | 202,585,000 | 154,799,000 | 83,693,000 | 61,404,000 | 48,254,000 | 34,492,000 | 24,930,000 | 13,747,000 | 7,140,000 | 11,280,000 |
| total assets | 260,503,000 | 327,456,000 | 233,138,000 | 257,415,000 | 214,165,000 | 169,275,000 | 96,785,000 | 76,409,000 | 50,454,000 | 37,252,000 | 28,068,000 | 18,153,000 | 12,473,000 | 17,375,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 12,765,000 | 12,605,000 | 9,696,000 | 2,881,000 | 9,215,000 | 4,334,000 | 5,036,000 | 5,724,000 | 2,078,000 | 2,385,000 | 1,206,000 | 1,756,000 | 682,000 | 1,901,000 |
| Group/Directors Accounts | 8,636,000 | 7,165,000 | 4,588,000 | 3,776,000 | 1,909,000 | 604,000 | 0 | 21,000 | 97,000 | 48,000 | 92,000 | 138,000 | 0 | 7,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 2,975,000 | 2,875,000 | 2,871,000 | 2,650,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 70,977,000 | 74,976,000 | 62,225,000 | 62,304,000 | 57,615,000 | 82,316,000 | 43,928,000 | 36,121,000 | 26,092,000 | 16,394,000 | 13,259,000 | 9,459,000 | 7,435,000 | 7,646,000 |
| total current liabilities | 95,353,000 | 97,621,000 | 79,380,000 | 71,611,000 | 68,739,000 | 87,254,000 | 48,964,000 | 41,866,000 | 28,267,000 | 18,827,000 | 14,557,000 | 11,353,000 | 8,117,000 | 9,554,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 1,968,000 | 4,751,000 | 7,506,000 | 9,970,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 5,697,000 | 3,232,000 | 2,102,000 | 2,168,000 | 2,051,000 | 2,312,000 | 2,865,000 | 3,465,000 | 4,270,000 | 5,344,000 | 763,000 | 188,000 | 107,000 | 399,000 |
| total long term liabilities | 7,665,000 | 7,983,000 | 9,608,000 | 12,138,000 | 2,051,000 | 2,312,000 | 2,865,000 | 3,465,000 | 4,270,000 | 5,344,000 | 763,000 | 188,000 | 107,000 | 399,000 |
| total liabilities | 103,018,000 | 105,604,000 | 88,988,000 | 83,749,000 | 70,790,000 | 89,566,000 | 51,829,000 | 45,331,000 | 32,537,000 | 24,171,000 | 15,320,000 | 11,541,000 | 8,224,000 | 9,953,000 |
| net assets | 157,485,000 | 221,852,000 | 144,150,000 | 173,666,000 | 143,375,000 | 79,709,000 | 44,956,000 | 31,078,000 | 17,917,000 | 13,081,000 | 12,748,000 | 6,612,000 | 4,249,000 | 7,422,000 |
| total shareholders funds | 157,485,000 | 221,852,000 | 144,150,000 | 173,666,000 | 143,375,000 | 79,709,000 | 44,956,000 | 31,078,000 | 17,917,000 | 13,081,000 | 12,748,000 | 6,612,000 | 4,249,000 | 7,422,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 88,263,000 | 74,389,000 | 68,066,000 | 57,306,000 | 54,664,000 | 63,874,000 | 7,145,000 | 7,434,000 | 793,000 | -110,000 | -3,068,000 | -2,286,000 | -25,000 | -967,000 |
| Depreciation | 1,700,000 | 3,476,000 | 3,298,000 | 3,704,000 | 2,828,000 | 2,601,000 | 2,516,000 | 1,342,000 | 1,776,000 | 1,038,000 | 1,350,000 | 1,273,000 | 1,243,000 | 1,159,000 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -16,403,000 | -13,699,000 | -12,922,000 | -12,035,000 | -8,936,000 | -39,110,000 | -3,605,000 | -3,405,000 | -1,528,000 | -3,917,000 | 2,904,000 | -512,000 | -700,000 | -1,487,000 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 8,793,000 | 23,279,000 | 61,918,000 | -52,576,000 | -9,328,000 | 53,110,000 | -2,233,000 | 14,364,000 | 2,435,000 | 9,302,000 | 8,203,000 | 596,000 | 1,177,000 | 4,641,000 |
| Creditors | 160,000 | 2,909,000 | 6,815,000 | -6,334,000 | 4,881,000 | -702,000 | -688,000 | 3,646,000 | -307,000 | 1,179,000 | -550,000 | 1,074,000 | -1,219,000 | 1,901,000 |
| Accruals and Deferred Income | -3,999,000 | 12,751,000 | -79,000 | 4,689,000 | -24,701,000 | 38,388,000 | 7,807,000 | 10,029,000 | 9,698,000 | 3,135,000 | 3,800,000 | 2,024,000 | -211,000 | 7,646,000 |
| Deferred Taxes & Provisions | 2,465,000 | 1,130,000 | -66,000 | 117,000 | -261,000 | -553,000 | -600,000 | -805,000 | -1,074,000 | 4,581,000 | 575,000 | 81,000 | -292,000 | 399,000 |
| Cash flow from operations | 63,393,000 | 57,677,000 | 3,194,000 | 100,023,000 | 37,803,000 | 11,388,000 | 14,808,000 | 3,877,000 | 6,923,000 | -3,396,000 | -3,192,000 | 1,058,000 | -2,381,000 | 4,010,000 |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 1,471,000 | 2,577,000 | 812,000 | 1,867,000 | 1,305,000 | 604,000 | -21,000 | -76,000 | 49,000 | -44,000 | -46,000 | 138,000 | -7,000 | 7,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | -2,683,000 | -2,751,000 | -2,243,000 | 12,620,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 1,901,000 | -191,000 | -36,000 | 546,000 | 269,000 | -2,065,000 | 69,000 | 70,000 | 32,000 | -25,000 | -31,000 | -51,000 | 1,000 | 8,000 |
| cash flow from financing | 20,892,000 | 16,838,000 | 13,909,000 | 28,147,000 | 19,243,000 | 10,593,000 | 10,317,000 | 9,056,000 | 5,620,000 | 4,316,000 | 6,254,000 | 5,299,000 | -2,455,000 | 9,883,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -73,439,000 | 74,098,000 | -83,808,000 | 89,952,000 | 56,864,000 | 20,931,000 | 24,326,000 | -934,000 | 11,327,000 | 260,000 | 2,980,000 | 6,011,000 | -5,317,000 | 6,639,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -73,439,000 | 74,098,000 | -83,808,000 | 89,952,000 | 56,864,000 | 20,931,000 | 24,326,000 | -934,000 | 11,327,000 | 260,000 | 2,980,000 | 6,011,000 | -5,317,000 | 6,639,000 |
gilead sciences europe ltd. Credit Report and Business Information
Gilead Sciences Europe Ltd. Competitor Analysis
Perform a competitor analysis for gilead sciences europe ltd. by selecting its closest rivals, whether from the ADMINISTRATIVE AND SUPPORT SERVICE ACTIVITIES sector, other mega companies, companies in UB11 area or any other competitors across 12 key performance metrics.
gilead sciences europe ltd. Ownership
GILEAD SCIENCES EUROPE LTD. group structure
Gilead Sciences Europe Ltd. has no subsidiary companies.
Ultimate parent company
GILEAD SCIENCES INC
#0135210
GILEAD SCIENCES IRELAND UNLIMITED COMPAN
IE259755
2 parents
GILEAD SCIENCES EUROPE LTD.
05510315
gilead sciences europe ltd. directors
Gilead Sciences Europe Ltd. currently has 4 directors. The longest serving directors include Mr Andrew Dickinson (Oct 2019) and Mr John Jorden (Jun 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Andrew Dickinson | United Kingdom | 54 years | Oct 2019 | - | Director |
| Mr John Jorden | United Kingdom | 40 years | Jun 2023 | - | Director |
| Mr Hans Stucker | 51 years | Jun 2023 | - | Director | |
| Ms Janet Dorling | 50 years | Jun 2023 | - | Director |
P&L
December 2022turnover
343.7m
+16%
operating profit
88.3m
+19%
gross margin
38.8%
+3.34%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
157.5m
-0.29%
total assets
260.5m
-0.2%
cash
129.9m
-0.36%
net assets
Total assets minus all liabilities
gilead sciences europe ltd. company details
company number
05510315
Type
Private limited with Share Capital
industry
82990 - Other business support service activities n.e.c.
incorporation date
July 2005
age
19
incorporated
UK
accounts
Full Accounts
ultimate parent company
previous names
N/A
last accounts submitted
December 2022
address
2 roundwood avenue, stockley park, uxbridge, middlesex, UB11 1AF
accountant
-
auditor
ERNST & YOUNG
gilead sciences europe ltd. Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to gilead sciences europe ltd..
gilead sciences europe ltd. Companies House Filings - See Documents
| date | description | view/download |
|---|
